What is Alopexx?

Alopexx is an investment, management, and development company focused on health care opportunities

Our Strategy

Alopexx partners with innovative entrepreneurs to build successful new companies. We will in-license novel therapies or medical devices, serve as a lead investor or join a group of investors to advance important science. Alopexx will invest in assets at all stages of development.

Pharmaceuticals

Alopexx Pharmaceuticals, LLC was founded in 2006 to develop and commercialize a promising new alternative for the treatment andprevention of staphylococcal and other serious bacterial infections. The company obtained the rights for all antibodies developed against a proprietary antigenic target – dPNAG.  That target, developed by Dr. Gerald Pier at Harvard Medical School, holds great promise for the treatment of a wide range of infections.

» Read More

Oncology

Alopexx Oncology has licensed DI-Leu16-IL2 from Provenance Therapeutics.  DI-Leu16-IL2 is an immune therapeutic, a type of medication that fights cancer by enlisting the body's own immune system and is a fusion of two known cancer therapeutics (an anti-CD20 antibody and the cytokine IL2) using a well-developed, proprietary technology that creates an effect that is far more powerful than administering those therapeutics individually or in combination.

» Read More

Vaccine

Alopexx Vaccines, LLC was founded in 2010 to develop and commercialize a promising new vaccine for the prevention of bacterial infections in production and companion animals. The company has obtained the rights to develop animal vaccines against a proprietary antigenic target – dPNAG.

» Read More

Valerion Therapeutics

Valerion Therapeutics, formerly 4s3 Bioscience, is developing therapies for orphan genetic muscle diseases utilizing a novel antibody-based targeting system capable of enhanced intracellular delivery.   Demonstrated pre-clinical in vivo data with the company’s two lead product candidates validates the potential of Valerion's delivery platform for delivering muscle-protein fusions and treating multiple indications in the fields of muscular dystrophies and enzyme-deficiency disorders.

» Read More

Janus Biotherapeutics

Janus Biotherapeutics is developing a novel, orally available TLR 7/8/9 receptor antagonist for the treatment of autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome and psoriasis.

» Read More